-
Beryl Drugs Ltd. Announces Positive Clinical Results for Lead Oncology Drug Candidate
Beryl Drugs Ltd. (TSX: BRL) today announced positive clinical results from a Phase IIb trial evaluating its lead oncology drug candidate, BRL-123, in patients with advanced solid tumors. The trial met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) compared to the control arm.
-
Beryl Drugs Ltd. Raises $100 Million in Series C Financing
Beryl Drugs Ltd. (TSX: BRL) today announced that it has closed a $100 million Series C financing round led by new investor OrbiMed. The financing will be used to support the continued development of Beryl's lead oncology drug candidate, BRL-123, as well as the expansion of the company's clinical pipeline.
-
Beryl Drugs Ltd. Appoints New Chief Medical Officer
Beryl Drugs Ltd. (TSX: BRL) today announced the appointment of Dr. John Smith as its new Chief Medical Officer. Dr. Smith has over 20 years of experience in the pharmaceutical industry, including leadership roles at major pharmaceutical companies.
-
Beryl Drugs Ltd. Announces Positive Clinical Trial Results for New Cancer Drug
Beryl Drugs Ltd., a leading pharmaceutical company, today announced positive clinical trial results for its new cancer drug, BRL-123. The drug was found to be safe and effective in treating a variety of cancers, including lung cancer, breast cancer, and colon cancer. BRL-123 is a monoclonal antibody that targets a specific protein on cancer cells. The drug was found to be well-tolerated by patients, with no serious side effects reported. The company plans to file for regulatory approval for BRL-123 later this year.
-
Beryl Drugs Ltd. Acquires Biotech Company to Expand Pipeline
Beryl Drugs Ltd., a leading pharmaceutical company, today announced that it has acquired Biotech Company, a clinical-stage biotechnology company. The acquisition will add Biotech Company's pipeline of novel cancer drugs to Beryl's portfolio. The acquisition will also give Beryl access to Biotech Company's proprietary technology platform, which could lead to the development of new cancer treatments.
-
Beryl Drugs Ltd. Reports Strong Financial Results for 2022
Beryl Drugs Ltd., a leading pharmaceutical company, today reported strong financial results for 2022. The company's revenue increased by 15% to $10 billion. Net income increased by 20% to $2 billion. The company's strong financial performance was driven by the sales of its blockbuster cancer drug, BRL-100. BRL-100 is a monoclonal antibody that treats a variety of cancers. The drug has been well-received by patients and doctors alike.
-
Beryl Drugs Ltd. Announces Positive Phase II Results for Lead Candidate in Autoimmune Disease
Beryl Drugs Ltd. (Nasdaq: BERY) today announced positive top-line results from a Phase II clinical trial evaluating the safety and efficacy of BRL-123 in patients with moderate-to-severe rheumatoid arthritis.
-
Beryl Drugs Ltd. Receives FDA Orphan Drug Designation for BRL-123 in Treatment of Rare Autoimmune Disease
Beryl Drugs Ltd. (Nasdaq: BERY) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BRL-123 for the treatment of systemic lupus erythematosus (SLE).
-
Beryl Drugs Ltd. Announces Collaboration with Leading Academic Medical Center to Advance Research on Autoimmune Diseases
Beryl Drugs Ltd. (Nasdaq: BERY) today announced a collaboration with the Massachusetts General Hospital (MGH) to advance research on autoimmune diseases.
-
Beryl Drugs Ltd. Announces Positive Results for New Drug in Clinical Trial
Beryl Drugs Ltd., a leading pharmaceutical company, announced positive results from a clinical trial of its new drug, BRX-101, for the treatment of Alzheimer's disease. The study, which was conducted at multiple sites in the United States, involved 200 patients with mild to moderate Alzheimer's disease.
-
Beryl Drugs Ltd. Receives FDA Approval for New Drug
Beryl Drugs Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved its new drug, BRX-102, for the treatment of multiple myeloma. BRX-102 is a first-in-class, oral proteasome inhibitor that has been shown to be effective in treating patients with multiple myeloma who have become resistant to other therapies.
-
Beryl Drugs Ltd. Announces $100 Million Investment in New Research Facility
Beryl Drugs Ltd. announced a $100 million investment in a new research facility in Cambridge, Massachusetts. The facility will focus on developing new drugs for the treatment of cancer, Alzheimer's disease, and other serious diseases.
-
Beryl Drugs Receives FDA Approval for New Cancer Treatment
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Beryl Drugs' new cancer treatment, Beryl-101. Beryl-101 is indicated for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML).
-
Beryl Drugs Announces Positive Phase III Results for Alzheimer's Disease Treatment
Beryl Drugs has announced positive top-line results from the Phase III clinical trial of its Alzheimer's disease treatment, Beryl-201. The trial met its primary endpoint, demonstrating a statistically significant improvement in cognitive function in patients with mild to moderate Alzheimer's disease.
-
Beryl Drugs Partners with Leading Cancer Center for Immuno-Oncology Research
Beryl Drugs has entered into a strategic partnership with the Memorial Sloan Kettering Cancer Center (MSK) to develop and commercialize novel immuno-oncology therapies. The partnership will leverage Beryl Drugs' expertise in antibody-drug conjugates and MSK's world-leading research in immuno-oncology.